Xingrui Pharmaceutical completed a nearly $40 million Series B+ financing round.

36Kr learned that "Xingrui Medicine" has announced the completion of a nearly $40 million Series B+ financing round. This round of financing was co - invested by an industrial fund, Hillhouse Capital Ventures, LYFE Capital, Lilly Asia Ventures (LAV), Sherpa Capital, Source Code Capital, and Primavera Capital Group. The funds raised in this round will be mainly used to accelerate the clinical development of multiple in vivo CAR - T pipelines, promote the establishment of extra - hepatic delivery platforms for the lungs, intestines, and nervous system, and strengthen the company's innovative R & D layout in the field of mRNA therapy.